These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 10140661)
1. Color as a trademark under the Lanham Act: confusion in the circuits and the need for uniformity. Carraway JC Law Contemp Probl; 1994; 57(4):243-79. PubMed ID: 10140661 [No Abstract] [Full Text] [Related]
2. Delaying generic competition--corporate payoffs and the future of Plavix. Shuchman M N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945 [No Abstract] [Full Text] [Related]
3. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering. Paine CS Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807 [No Abstract] [Full Text] [Related]
4. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]
5. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II. Leary TB J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411 [TBL] [Abstract][Full Text] [Related]
6. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice? Shah S; Silva MA; Malloy MJ Nat Biotechnol; 2016 Jul; 34(7):716-9. PubMed ID: 27404880 [No Abstract] [Full Text] [Related]
9. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
11. Hospital competition and antitrust: the Federal Trade Commission staff report. Miles JJ Health Law Vigil; 1987 Jul; 10(14):6-10. PubMed ID: 10282648 [No Abstract] [Full Text] [Related]
12. Generics battle brand names over mortality of drug patents. Betz R J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008 [No Abstract] [Full Text] [Related]
13. General Electric may violate antitrust law with purchase of medical imaging business. Carter K Mod Healthc; 1986 Apr; 16(9):22. PubMed ID: 10276446 [No Abstract] [Full Text] [Related]
14. The health care industry and antitrust: a continuing exploration. Weissburg C; Waxman JM Rev Fed Am Hosp; 1983; 16(4):57, 60. PubMed ID: 10260804 [No Abstract] [Full Text] [Related]
15. Mergers and acquisitions in the health care industry. Duncheon MA; Goldman JS Health Law Vigil; 1986 Jul; 9(13):18-21. PubMed ID: 10277099 [No Abstract] [Full Text] [Related]
16. Antitrust in the health services industry: the first five years. Dolan AK Health Med Care Serv Rev; 1981-1982; 3(2-3):13, 15-24. PubMed ID: 10299261 [No Abstract] [Full Text] [Related]
17. The antitrust perspective on health industry competition. Miller FH J Health Hum Resour Adm; 1989; 12(1):128-48. PubMed ID: 10296433 [No Abstract] [Full Text] [Related]
18. The antitrust analysis of hospital mergers and the transformation of the hospital industry. Baker JB Law Contemp Probl; 1988; 51(2):93-164. PubMed ID: 10295967 [No Abstract] [Full Text] [Related]
19. The hard-selling supplier to the sick. Pillsbury AB Fortune; 1982 Jul; 106(2):56-61. PubMed ID: 10255942 [No Abstract] [Full Text] [Related]
20. Antitrust: medical device corporation liable for violating FTC order. Montgomery R J Law Med Ethics; 2002; 30(1):122-3. PubMed ID: 11905263 [No Abstract] [Full Text] [Related] [Next] [New Search]